⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

May 1, 2024Open Access

Supplementary Figure S6 from Jak2V617F Reversible Activation Shows Its Essential Requirement in Myeloproliferative Neoplasms

Andrew Dunbar Robert L. Bowman Young C. Park Kavi O’Connor Franco Izzo Robert M. Myers Abdul Karzai Zachary Zaroogian Won Jun Kim Inés Fernández-Maestre Michael R. Waarts Abbas Nazir Wenbin Xiao Tamara Codilupi Max Brodsky Mirko Farina Louise Cai Sheng F. Cai Benjamin Wang Wenbin An Julie L. Yang Shoron Mowla Shira E. Eisman Amritha Varshini Hanasoge Somasundara Jacob L. Glass Tanmay Mishra Remie Houston Emily Guzzardi Anthony R. Martinez Benitez Aaron D. Viny Richard P. Koche Sara C. Meyer Dan A. Landau Ross L. Levine

View Full Paper

Ask AI

Bookmark

Share

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Abstract

Acute phenotypic and transcriptional changes following Jak2V617F reversion

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Dunbar et al. (2024) studied this question.

synapsesocial.com/papers/68e6c4bab6db643587643a61 https://doi.org/10.1158/2159-8290.25728915.v1

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure S6 from Jak2<sup>V617F</sup> Reversible Activation Shows Its Essential Requirement in Myeloproliferative Neoplasms2024
2Supplementary Figure S2 from Jak2<sup>V617F</sup> Reversible Activation Shows Its Essential Requirement in Myeloproliferative Neoplasms2024
3Supplementary Figure S2 from Jak2<sup>V617F</sup> Reversible Activation Shows Its Essential Requirement in Myeloproliferative Neoplasms2024
4Supplementary Figure S1 from Jak2<sup>V617F</sup> Reversible Activation Shows Its Essential Requirement in Myeloproliferative Neoplasms2024
5Supplementary Figure S1 from Jak2<sup>V617F</sup> Reversible Activation Shows Its Essential Requirement in Myeloproliferative Neoplasms2024